F-star Therapeutics Total Revenue

As of the most recent data (September 2022), FSTX shows a total revenue of $21M. That compares with $3.8M in the prior-year period — up 452.7% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FSTX's total revenue is now $21M (was $3.8M) — a 452.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether F-star Therapeutics is outperforming or lagging.

The Healthcare sector average total revenue is about $110B. F-star Therapeutics is at $21M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how FSTX stacks up against individual peers as well.

Tracking FSTX's total revenue over time shows whether F-star Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $21M That compares with $3.8M in the prior-year period — up 452.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has F-star Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $21M) with ownership activity and broader fundamentals.